Your cart is empty.
Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
Männedorf, Switzerland, April 8, 2025 – IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a strategic partnership with Grifols, a global healthcare company and leading producer of plasma-derived medicines and innovative diagnostic solutions, to transform the specialty diagnostics market.
Under this collaboration, IBL will develop biomarker panels for specialty diagnostics based on Grifols’ random access, single molecule counting (SMC) platform. These panels will address key customer needs in specialty diagnostics, offering solutions for laboratories and patients alike. The agreement includes a framework for product development, manufacturing and commercialization, ensuring a reliable and efficient delivery to the market.
The project brings together IBL’s expertise in specialty diagnostic assay development and Grifols’ leadership in diagnostic instrumentation to produce a state-of-the-art system. The collaboration encompasses:
Achieving better specialty diagnostics
Specialty diagnostics are often performed outside the high-throughput, automated workflows of the core laboratory, requiring specialized equipment and processes to handle low-volume, high-value tests. This partnership streamlines these processes by combining multiple specialty diagnostic parameters into a single workflow. Grifols’ random access technology allows laboratories to process tests as soon as samples arrive, eliminating delays associated with batching and enabling faster, more efficient diagnostics that enhance patient care.
“Partnering with Grifols allows us to scale healthcare innovation globally,” said Mukta Acharya, Head of Tecan’s Life Sciences business division. “By leveraging IBL’s entrepreneurial spirit and technological expertise, we’re addressing unmet needs in specialty diagnostics. Together, we’re creating solutions that empower laboratories and enhance patient journeys with reliable and sensitive diagnostics.”
“Our collaboration with IBL demonstrates our commitment to our strategic plan for developing innovative clinical diagnostic solutions,” said Guillermo Marco-Gardoqui, SVP Diagnostic Operations and Strategy at Grifols. “By integrating IBL’s biomarker panels with the advanced capabilities of the SMC Platform, we are enhancing clinical workflows and addressing critical gaps in patient care.”
Driving innovation
The panels under development respond to customer feedback, ensuring they meet the needs of both laboratories and patients. This first-in-class random access system with SMC technology introduces a clinical market solution that integrates seamlessly into the core lab, enhancing workflow efficiency and allowing for ultra-highly sensitive, multiplexed assays. The partnership demonstrates Tecan’s commitment to improving people’s lives and health by enabling customers to scale healthcare innovation globally. It highlights IBL’s leading position in specialty diagnostics and reflects Tecan’s commitment to advancing modern, multiplexed diagnostic solutions.
About Tecan and IBL International
IBL International GmbH, part of the Tecan Group, specializes in the development and production of innovative immunoassays and diagnostic solutions. It is recognized for its expertise in specialty diagnostics, helping laboratories address critical challenges in healthcare.
Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has 3,300 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2024, Tecan generated sales of CHF 934 million (USD 1,062 million; EUR 984 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
About Grifols Diagnostic Solutions Inc.
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.
Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.
A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with over 390 across North America, Europe, Africa and the Middle East, and China.
As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.
Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.
The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).
For more information about Grifols, please visit grifols.com.
For further information:
Tecan Group
Martin Brändle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
investor@tecan.com
Grifols Press Office
media@grifols.com
Tel. +34 93 571 00 02